Bone effects of metformin monotherapy and its combination with teneligliptin: A 12-week follow-up study in patients with type 2 diabetes mellitus
Authors' conclusion
The positive bone outcome of metformin or teneligliptin was linked to bone resorption rather than bone formation and was independent of changes in HbA1c or PTD. However, these results must be confirmed with well-designed RCTs with more extended follow-up periods.
Study context
- Population
- Patients with T2DM, tertiary care teaching hospital in New Delhi, North India
- Exposure
- Metformin monotherapy vs metformin + teneligliptin
- Outcome
- Bone turnover markers (bone formation and resorption markers), IL-6 and PTD
- Follow-up
- Baseline and 12 weeks
Methodological detailssingle-centre, 12-week follow-up
- Single-centre
- 12-week follow-up
Main finding
As reported in the abstract
Bone turnover markers, change from baseline · 12 weeks
- Metformin: β-CTX, sRANKL, IL-6 and PTD decreased significantly; no significant changes in P1NP, OC, BAP or OPG
- Metformin + teneligliptin: BAP, β-CTX, sRANKL, IL-6 and PTD decreased significantly; no significant changes in P1NP, OC or OPG
Observational data: associations, not effects.
Further findings
HbA1c · baseline to 12 weeks
- HbA1c decreased significantly in both groups
Original publication
Bone effects of metformin monotherapy and its combination with teneligliptin: A 12-week follow-up study in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. Published 13 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →